07/17/14 - 10:33 AM EDT
It's not often an investor gets the opportunity to buy a biotech stock with two blockbuster indications in the pipeline and major catalysts only months away at such a discount.
11/04/13 - 10:06 AM EST
Biotech trader Dan Rosenblum believes the recent selloff in Sarepta is a tremendous buying opportunity.
04/25/13 - 09:25 AM EDT
Contributor Dan Rosenblum believes Sarepta's upside potential far outweighs the risk in the stock.
03/05/13 - 10:39 AM EST
The exon-skipping drug technology is worth a lot more than just eteplirsen alone.
12/20/12 - 07:30 AM EST
Insiders at Auxilium and Aveo appear to be betting on turnarounds for both stocks in the next year.
11/07/12 - 11:28 AM EST
TheStreet contributor Dan Rosenblum explains why he still likes BioMarin and Lexicon Pharma.
11/05/12 - 08:00 AM EST
Sunshine's C-Pulse is a heart-assist device for patients who fall between the cracks of current therapy.
10/16/12 - 06:10 AM EDT
Lexicons mid-stage diabetes drug blocks the reabsorption of blood sugar.
09/25/12 - 07:03 AM EDT
TheStreet contributor Dan Rosenblum explains why Biomarin is a very busy biotech.
09/18/12 - 07:13 AM EDT
A hospital-based sepsis test is the launching pad for Nanosphere.